Journey Medical shares are trading higher after the company announced topline data from the Phase 1 clinical trial assessing the impact of DFD-29 on microbial flora of healthy adult subjects.
Portfolio Pulse from Benzinga Newsdesk
Journey Medical announced positive topline data from the Phase 1 clinical trial of DFD-29, which assessed its impact on microbial flora in healthy adult subjects. This news has led to an increase in the company's share price.
June 13, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Journey Medical's positive Phase 1 clinical trial data for DFD-29 has led to an increase in the company's share price.
The positive topline data from the Phase 1 clinical trial of DFD-29 indicates that the drug has potential in the market. This news has led to increased investor confidence in Journey Medical, resulting in a higher share price for the company.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100